Although we have found no alteration of cell proliferation, apoptosis, or migration upon Sfrp1 silencing in vitro, given the known involvement of Wnt signaling in certain types of cancer, translation of this method to the clinic will require further molecular analysis such as analysis of important tumor suppressor genes (p53), karyotyping, etc. and extensive in vivo pre-clinical studies to ensure long-term safety of the treatment. The gene discussed is TP53; the disease is cancer.